Olmesartan protects endothelial cells against oxidative stress-mediated cellular injury

Clinical and Experimental Nephrology

Volumn 19, Issue 6, 2015, Pages 1007-1014

  Kadowaki, Daisuke ^a   Anraku, Makoto ^b   Sakaya, Moe ^a   Hirata, Sumio ^a   Maruyama, Toru ^a   Otagiri, Masaki ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b SOJO UNIVERSITY   (Japan)

Author keywords

Antioxidant; Endothelial cell; Hemodialysis; Olmesartan; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ADVANCED OXIDATION PROTEIN PRODUCT; ANGIOTENSIN II; CALPHOSTIN C; DIPHENYLIODONIUM SALT; FLUORESCENT DYE; HYDROGEN PEROXIDE; INDICAN; LIPOPOLYSACCHARIDE; OLMESARTAN; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; VASCULOTROPIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIOXIDANT; IMIDAZOLE DERIVATIVE; OXIDIZING AGENT; TETRAZOLE DERIVATIVE; VASCULOTROPIN A;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL DAMAGE; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; FLUORESCENCE; HEMODIALYSIS; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PROTEIN SECRETION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULITIS; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; FEMALE; METABOLISM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIOXIDANTS; CELL SURVIVAL; ENDOTHELIAL CELLS; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROGEN PEROXIDE; IMIDAZOLES; NADPH OXIDASE; OXIDANTS; OXIDATIVE STRESS; PROTEIN KINASE C; REACTIVE OXYGEN SPECIES; TETRAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84951907127     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-015-1111-5     Document Type: Article

References (34)

1. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–60.
2. Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens. 2006;24(2):403–8.
3. Akhrass PR, McFarlane SI. Telmisartan and cardioprotection. Vasc Health Risk Manag. 2011;7:677–83.
4. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol. 2002;13(10):2478–87.
5. Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol. 2003;14(5):1212–22.
6. Honda H, Hosaka N, Aoshima Y, Hirai Y, Michihata T, Akizawa T. Olmesartan medoxomil is associated with decreased plasma AGEs, pentosidine, and N-(epsilon)-carboxymethyl-lysine levels in hemodialysis patients. Clin Exp Hypertens. 2012;34(1):17–23.
7. Kadowaki D, Anraku M, Tasaki Y, Kitamura K, Wakamatsu S, Tomita K, et al. Effect of olmesartan on oxidative stress in hemodialysis patients. Hypertens Res. 2007;30(5):395–402.
8. Kadowaki D, Anraku M, Tasaki Y, Taguchi K, Shimoishi K, Seo H, et al. Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats. Biol Pharm Bull. 2009;32(12):2041–5.
9. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74(6):1141–8.
10. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation. 2001;103(3):448–54.
11. Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol. 2003;42(5):905–10.
12. Nockher WA, Scherberich JE. Monocyte cell-surface CD14 expression and soluble CD14 antigen in hemodialysis: evidence for chronic exposure to LPS. Kidney Int. 1995;48(5):1469–76.
13. Li H, Forstermann U. Structure-activity relationship of staurosporine analogs in regulating expression of endothelial nitric-oxide synthase gene. Mol Pharmacol. 2000;57(3):427–35.
14. Heitzer T, Wenzel U, Hink U, Krollner D, Skatchkov M, Stahl RA, et al. Increased NAD(P)H oxidase-mediated superoxide production in renovascular hypertension: evidence for an involvement of protein kinase C. Kidney Int. 1999;55(1):252–60.
15. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27–31.
16. Marumo T, Schini-Kerth VB, Busse R. Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes. 1999;48(5):1131–7.
17. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 1999;56(3):794–814.
18. Iwai M, Chen R, Li Z, Shiuchi T, Suzuki J, Ide A, et al. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation. 2005;112(11):1636–43.
19. Ohshima K, Mogi M, Nakaoka H, Iwanami J, Min LJ, Kanno H, et al. Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin-(1-7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade. Hypertension. 2014;63(3):e53–9.
20. Shimada H, Kitamura K, Anraku M, Miyoshi T, Adachi M, Tuyen DG, et al. Effect of telmisartan on ambulatory blood pressure monitoring, plasma brain natriuretic peptide, and oxidative status of serum albumin in hemodialysis patients. Hypertens Res. 2005;28(12):987–94.
21. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem. 2001;276(10):7614–20.
22. Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, et al. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension. 2004;43(2):263–9.
23. Wang X, Khaidakov M, Ding Z, Mitra S, Lu J, Liu S, et al. Cross-talk between inflammation and angiotensin II: studies based on direct transfection of cardiomyocytes with AT1R and AT2R cDNA. Exp Biol Med (Maywood). 2012;237(12):1394–401.
24. Bagi Z, Erdei N, Koller A. High intraluminal pressure via H2O2 upregulates arteriolar constrictions to angiotensin II by increasing the functional availability of AT1 receptors. Am J Physiol Heart Circ Physiol. 2008;295(2):H835–41.
25. Cao W, Xu J, Zhou ZM, Wang GB, Hou FF, Nie J. Advanced oxidation protein products activate intrarenal renin-angiotensin system via a CD36-mediated, redox-dependent pathway. Antioxid Redox Signal. 2013;18(1):19–35.
26. Sun CY, Chang SC, Wu MS. Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PLoS One. 2012;7(3):e34026.
27. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999;138(5 Pt 2):S419–20.
28. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, et al. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia. 2006;49(12):3094–9.
29. Nakamura K, Yamagishi S, Nakamura Y, Takenaka K, Matsui T, Jinnouchi Y, et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res. 2005;70(3):137–41.
30. Ohgami N, Nagai R, Ikemoto M, Arai H, Kuniyasu A, Horiuchi S, et al. Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J Biol Chem. 2001;276(5):3195–202.
31. Fujita M, Okuda H, Tsukamoto O, Asano Y, Hirata YL, Kim J, et al. Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells. Arterioscler Thromb Vasc Biol. 2006;26(10):e138–42.
32. Hayek T, Aviram M, Heinrich R, Sakhnini E, Keidar S. Losartan inhibits cellular uptake of oxidized LDL by monocyte-macrophages from hypercholesterolemic patients. Biochem Biophys Res Commun. 2000;273(2):417–20.
33. Tanifuji C, Suzuki Y, Geot WM, Horikoshi S, Sugaya T, Ruiz-Ortega M, et al. Reactive oxygen species-mediated signaling pathways in angiotensin II-induced MCP-1 expression of proximal tubular cells. Antioxid Redox Signal. 2005;7(9–10):1261–8.
34. Teng J, Fukuda N, Suzuki R, Takagi H, Ikeda Y, Tahira Y, et al. Inhibitory effect of a novel angiotensin II type 1 receptor antagonist RNH-6270 on growth of vascular smooth muscle cells from spontaneously hypertensive rats: different anti-proliferative effect to angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol. 2002;39(2):161–71.